Emerging technologies: Polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter

EuroIntervention

Volumn 9, Issue 1, 2013, Pages 146-156

  Lemos, Pedro A ^a   Farooq, Vasim ^b   Takimura, Celso K ^a   Gutierrez, Paulo S ^a   Virmani, Renu ^c   Kolodgie, Frank ^c   Christians, Uwe ^d   Kharlamov, Alexander ^b   Doshi, Manish ^e   Sojitra, Prakash ^e   Van Beusekom, Heleen M M ^b   Serruys, Patrick W ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CVPATH INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e Envision Scientific   (India)

Author keywords

Delivery systems; Drug release profile; Drug eluting balloon; Drug eluting stent; Nanoparticles

Indexed keywords

NANOCARRIER; PHOSPHOLIPID; RAPAMYCIN; BIOMATERIAL; CARDIOVASCULAR AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; NANOPARTICLE;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BALLOON CATHETER; BALLOON DILATATION; BARE METAL STENT; BLOOD VESSEL WALL; CONTROLLED DRUG RELEASE; CORONARY STENT; DEVICE SAFETY; DRUG BLOOD LEVEL; DRUG COATING; DRUG ELUTING STENT; DRUG PENETRATION; DRUG TISSUE LEVEL; ENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PARTICLE SIZE; PHOSPHOLIPID BILAYER; ANIMAL; BLOOD; CATHETER; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DEVICES; DISEASE MODEL; FEMORAL ARTERY; ILIAC ARTERY; KINETICS; MALE; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RABBIT; SWINE; TISSUE DISTRIBUTION; VALIDATION STUDY; VASCULAR SYSTEM INJURIES; BLOOD VESSEL INJURY; EQUIPMENT; INJURY; METABOLISM; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; EQUIPMENT DESIGN; HUMAN; PRODUCT DEVELOPMENT; SIROLIMUS ELUTING BALLOON;

ANGIOPLASTY, BALLOON; ANIMALS; CARDIOVASCULAR AGENTS; CATHETERS; COATED MATERIALS, BIOCOMPATIBLE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG-ELUTING STENTS; FEMORAL ARTERY; ILIAC ARTERY; KINETICS; MALE; NANOPARTICLES; PHOSPHOLIPIDS; RABBITS; SIROLIMUS; SWINE; TISSUE DISTRIBUTION; VASCULAR SYSTEM INJURIES;

EID: 84877859110     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I1A21     Document Type: Article

References (21)

1. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005;46:253-60. (Pubitemid 40966852)
2. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. 2011;4:195-205.
3. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56:S43-78.
4. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS Jr, Ribeiro EE, Martinez EE; PAINT trial investigators. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv. 2009;74:665-73.
5. Rome JJ, Shayani V, Flugelman MY, Newman KD, Farb A, Virmani R, Dichek DA. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb. 1994;14:148-61.
6. Nasser TK, Wilensky RL, Mehdi K, March KL. Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: quantitation and localization by confocal scanning laser microscopy. Am Heart J. 1996;131:892-8. (Pubitemid 26135751)
7. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, Bruining N, Sabate M, Serruys PW; ITALICS Trial. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol. 2002;39:281-7. (Pubitemid 34084634)
8. Camenzind E, Bakker WH, Reijs A, van Geijlswijk IM, Boersma E, Kutryk MJ, Krenning EP, Roelandt JR, Serruys PW. Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. Circulation. 1997;96:154-65. (Pubitemid 27298417)
9. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1997;14:1568-73. (Pubitemid 28009208)
10. Cebrián V, Martín-Saavedra F, Yagüe C, Arruebo M, Santamaría J, Vilaboa N. Size-dependent transfection efficiency of PEI-coated gold nanoparticles. Acta Biomater. 2011;7:3645-55.
11. Aoki J, Ong AT, Abizaid A, den Heijer P, Bonnier H, McClean DR, Verheye S, Belardi J, Condado JA, Pieper M, Sousa JE, Bressers M, Symons J, Litvack F, Sianos G, Serruys PW. One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). EuroIntervention. 2005;1:165-72.
12. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 2002;233:51-9. (Pubitemid 34230418)
13. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis. 2005;178:67-73. (Pubitemid 39600817)
14. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci. 1998;87:1229-34. (Pubitemid 28455614)
15. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J Control Release. 1998;54:201-11. (Pubitemid 28342699)
16. Westedt U, Barbu-Tudoran L, Schaper AK, Kalinowski M, Alfke H, Kissel T. Effects of different application parameters on penetration characteristics and arterial vessel wall integrity after local nanoparticle delivery using a porous balloon catheter. Eur J Pharm Biopharm. 2004;58:161-8. (Pubitemid 38781017)
17. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270-8. (Pubitemid 40982311)
18. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R; Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867-73.
19. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373-85. (Pubitemid 39303937)
20. Gunn J, Arnold N, Chan KH, Shepherd L, Cumberland DC, Crossman DC. Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart. 2002;88:401-5.
21. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv. 2008;1:143-53.